Structured lifestyle education to support weight loss for people with schizophrenia, schizoaffective disorder and first episode psychosis: the STEPWISE RCT

Richard IG Holt,1,2* Daniel Hind,3 Rebecca Gossage-Worrall,3 Michael J Bradburn,3 David Saxon,4 Paul McCrone,5 Tiyi A Morris,5 Angela Etherington,6 David Shiers,7,8 Katharine Barnard,9 Lizzie Swaby,3 Charlotte Edwardson,10 Marian E Carey,11 Melanie J Davies,10 Christopher M Dickens,12 Yvonne Doherty,11,13 Paul French,7 Kathryn E Greenwood,14,15 Sridevi Kalidindi,16 Kamlesh Khunti,11 Richard Laugharne,17 John Pendlebury,18 Shanaya Rathod,19 Najma Siddiqi,20,21 Stephen Wright,22 Glenn Waller,23,24 Fiona Gaughran,25,26 Janette Barnett11 and Alison Northern11

1Human Development and Health AcademicUnit, Faculty of Medicine, University of Southampton, Southampton, UK  
2University Hospital Southampton NHS Foundation Trust, Southampton, UK  
3Clinical Trials Research Unit, University of Sheffield, Sheffield, UK  
4School of Health and Related Research, University of Sheffield, Sheffield, UK  
5King's Health Economics, Institute of Psychiatry, Psychology & Neuroscience, King’s College London, London, UK  
6Independent service user consultant  
7Psychosis Research Unit, Greater Manchester Mental Health NHS Foundation Trust, Manchester, UK  
8School of Health Sciences, Division of Psychology and Mental Health, University of Manchester, Manchester, UK  
9Faculty of Health & Social Sciences, Bournemouth University, Poole, UK  
10Diabetes Research Centre, University of Leicester, Leicester, UK  
11Leicester Diabetes Centre, University Hospitals of Leicester, Leicester, UK  
12Institute of Health Research, University of Exeter Medical School, Exeter, UK  
13Psychological Medicine, York Teaching Hospital NHS Foundation Trust, York, UK  
14Sussex Partnership NHS Foundation Trust, Worthing, UK
Declared competing interests of authors: Richard IG Holt received fees for lecturing, consultancy work and attendance at conferences from the following companies: Boehringer Ingelheim (Ingelheim am Rhein, Germany), Eli Lilly and Company (Indianapolis, IN, USA), Janssen Pharmaceutica (Beerse, Belgium), Lundbeck (Copenhagen, Denmark), Novo Nordisk (Bagsvaerd, Denmark), Novartis (Basel, Switzerland), Otsuka Pharmaceutical Co., Ltd (Tokyo, Japan), Sanofi-Aventis (Paris, France) and Sunovion Pharmaceuticals, Inc. (Marlborough, MA, USA). Paul French is a member of the National Institute for Health Research (NIHR) Health Technology Assessment Mental, Psychological and Occupational Health funding panel. Melanie J Davies and Kamlesh Khunti are members of a NIHR Clinical Trials Unit. Melanie J Davies reports personal fees from Novo Nordisk, Sanofi-Aventis, Eli Lilly and Company, Merck Sharp & Dohme (Kenilworth, NJ, USA), Boehringer Ingelheim, AstraZeneca (Cambridge, UK), Janssen Pharmaceutica, Servier Laboratories (Neuilly-sur-Seine, France), Mitsubishi Tanabe Pharma Corporation (Tokyo, Japan) and Takeda Pharmaceuticals International Inc. (Canton of Zürich, Switzerland) and grants from Novo Nordisk, Sanofi-Aventis, Eli Lilly and Company, Boehringer Ingelheim and Janssen Pharmaceutica. Kamlesh Khunti has received fees for consultancy and being a speaker for Novartis, Novo Nordisk, Sanofi-Aventis, Eli Lilly and Company, Servier Laboratories and Merck Sharp & Dohme. He has received grants in support of investigator and investigator-initiated trials from Novartis, Novo Nordisk, Sanofi-Aventis, Eli Lilly and Company, Pfizer (New York, NY, USA), Boehringer Ingelheim and Merck Sharp & Dohme. Kamlesh Khunti has also received funds for research and honoraria for speaking at meetings, and has served on advisory boards for Eli Lilly and Company, Sanofi-Aventis, Merck Sharp & Dohme and Novo Nordisk. David Shiers is an expert advisor to the National Institute for Health and Care Excellence (NICE) centre for guidelines, a board member of the National Collaborating Centre for Mental Health (NCCMH) and a clinical advisor (on a paid consultancy basis) to the National Clinical Audit of Psychosis (NCAP); any views given in this report are personal and not those of NICE, NCCMH or NCAP. David Shiers reports personal fees from the Wiley-Blackwell publication Promoting Recovery in Early Psychosis, 2010 (ISBN 978-1-4051-4894-8), as he is a joint editor in receipt of royalties. John Pendelbury received personal fees for involvement in the study from a NIHR grant; he reports personal fees from the Greater Manchester Mental Health NHS foundation trust outside the submitted work and has published papers in the area of weight management and physical health related to mental health. Marian E Carey and Yvonne Doherty report being employed by the Leicester Diabetes Centre, an organisation (employer) jointly hosted by a NHS hospital trust and the University of Leicester and which is the holder (through the University of Leicester) of the copyright of the STEPWISE programme and of the Diabetes Education and Self-Management for Ongoing and Newly
Diagnosed (DESMOND) suite of programmes, training and intervention fidelity framework that were used in this study. Fiona Gaughran reports personal fees from Otsuka and Lundbeck and personal fees and non-financial support from Sunovion, outside the submitted work, and has a family member with professional links to Eli Lilly and Company and GlaxoSmithKline (Brentford, UK), including shares.
Scientific summary

Background

Schizophrenia is a psychotic illness that affects around 1% of the population. The prevalence of obesity in people with schizophrenia is approximately twofold higher than that in the general population and is associated with higher levels of morbidity, especially cardiovascular disease, diabetes mellitus and early mortality.

Objectives

- To develop a group-based, structured self-management lifestyle education programme for people with schizophrenia, schizoaffective disorder and first episode psychosis.
- To conduct a multicentre randomised controlled trial (RCT) to investigate whether or not the intervention leads to a clinically important difference in weight change, as well as physical activity and diet, compared with usual care.
- To conduct a mixed-methods process evaluation to explore intervention delivery and participant and facilitator experiences, and to explain discrepancies between expected and observed outcomes.
- To conduct an economic evaluation of the intervention.
- To assess the fidelity of intervention delivery when undertaken at 10 different sites.

Design

Intervention development
The intervention development was guided by the Medical Research Council framework for complex interventions: (1) identifying the evidence base through a literature review; (2) identifying/developing a theory and modelling the process and outcomes, through consultation with service users and health professionals; and (3) four plan–do–study–act cycles incorporating qualitative interviews.

Randomised controlled trial
The trial was a two-arm, parallel-group RCT with a 1 : 1 allocation ratio, using web-based randomisation and with the principal investigator and analysts being blinded to allocation until after the final analysis.

Mixed-methods process evaluation
The process evaluation used three main approaches:

1. logic modelling, integrating contextual factors with the National Institute for Health Behaviour Change Consortium fidelity framework and Linnan and Steckler’s process evaluation framework
2. a qualitative single-case design, with the unit of analysis variably at the participant level (n = 24 participants) and at the level of the experimental intervention programme (n = 20 facilitator interviews)
3. a triangulation protocol to compare quantitative process data with qualitative findings.

Economic evaluation
The economic evaluation was undertaken from a health and social care and societal perspective and included the costs of medicines and NHS professionals in primary and community care and inpatient settings, as well as social care costs (including costs of education, and employment and informal care). The cost-effectiveness of the physical activity and healthy eating programme was assessed by combining costs with the primary outcome and quality-adjusted life-years (QALYs) generated from the EuroQol-5 Dimensions, five-level version (EQ-5D-5L) questionnaire.
**Fidelity of the intervention delivery**
Fidelity was assessed by facilitator talk time and direct observation of the facilitator behaviour and conduct at sessions.

**Setting**
Community settings in 10 UK mental health NHS trusts.

**Participant selection and recruitment**
Potential participants were eligible for inclusion if they were adults aged ≥ 18 years with a diagnosis of schizophrenia, schizoaffective disorder or first episode psychosis, were being treated with an antipsychotic drug, were willing and able to give consent and to attend group education sessions delivered in English, and had a body mass index of ≥ 25 kg/m² (≥ 23 kg/m² for adults with South Asian and Chinese backgrounds) or were concerned about weight. People with physical illnesses that could seriously reduce life expectancy or affect metabolic measures or weight gain were excluded. Those with a primary diagnosis of a learning disability, who were currently pregnant or < 6 months post partum, who had significant alcohol or substance misuse or a (tentative) diagnosis of psychotic depression or mania or were currently (or within the past 3 months) engaged in a systematic weight management programme were also excluded.

**Intervention development study**
Twenty-four service users were recruited between May and December 2014 in four waves at one centre (Sheffield) to refine a prototype intervention before the RCT.

**Randomised controlled trial**
Between 10 March 2015 and 31 March 2016, 1223 adults with schizophrenia, schizoaffective disorder or first episode psychosis were screened for eligibility. A total of 423 consented to participate in the trial and 414 participants (target: \( n = 396 \)) were randomised (intervention arm, \( n = 208 \) participants; usual care, \( n = 206 \) participants).

**Interventions**
All participants received standardised written lifestyle information about diet, physical activity, smoking and alcohol use. The use of external weight loss programmes was permitted at the individual level.

The intervention group received a complex intervention based on Bandura’s self-efficacy theory, Leventhal’s self-regulation theory and Marlatt and Gordon’s relapse prevention model. The programme comprised (1) four 2.5-hour group-based structured lifestyle self-management education sessions, 1 week apart, facilitated by trained professionals delivering manualised content; (2) fortnightly support contacts from facilitators (face to face or via telephone, mail or e-mail, by participant preference); and (3) three 2.5-hour group booster sessions delivered at 3-monthly intervals post core sessions, reinforcing further behaviour change/self-management strategies.

The control group received treatment as usual, captured through a survey at the site level and a health and social care resource questionnaire.
Main outcome measures

The main outcome measures were weight change (primary outcome at 12 months), body mass index, waist circumference, objectively measured physical activity [wrist-worn GENEActiv (Activinsights, Kimbolton, UK) accelerometer], adapted Dietary Instrument for Nutrition Education questionnaire, blood pressure, fasting glucose, lipid profile, glycated haemoglobin, health state utility (EQ-5D-5L), Short Form questionnaire-36 items, Brief Illness Perception Questionnaire [B-IPQ] weight], Brief Psychiatric Rating Scale, health and social care resource use (Client Service Receipt Inventory), Patient Health Questionnaire 9-item depression scale, weight loss programmes, session feedback (intervention only) and adverse events. Analyses were undertaken on an intention-to-treat basis, with the treatment effect adjusted for the baseline value, recruiting site, years since the person started antipsychotic treatment and the clustering effect of the course attended.

Results

The trial closed on 31 March 2017, with 341 (81.6%) participants completing the trial. Forty-seven (25 intervention, 22 control) participants withdrew consent, three died (intervention) and 21 (11 intervention and 10 control) participants were lost to follow-up. The intention-to-treat analysis excluded two participants (control); one was erroneously randomised, having previously not consented, and one withdrew all consent to use their data. Therefore, 412 (207 intervention and 205 control) participants were included in the analyses. Two hundred and ten participants (51.0%) were male, 349 participants (84.7%) were white European and the average age was 40 years.

Randomised controlled trial outcomes

At baseline, the groups were well balanced; however, the intervention group participants were, on average, 3 kg heavier at baseline, which is partially explained by the higher proportion of men in the intervention arm (55.6% vs. 46.3%). Three hundred and forty-nine participants (84.7%) had a diagnosis of schizophrenia or schizoaffective disorder and 63 (15.3%) were categorised as having first episode psychosis. One hundred and eleven intervention group participants (53.6%) attended three or more core sessions and one or more booster sessions; 36 participants (17.4%) did not attend any intervention sessions.

After 12 months, the primary outcome of weight change (kg) was almost identical between the trial arms, with a non-significant mean reduction in weight of 0.47 kg in the intervention group and 0.51 kg in the control group (difference = 0.0 kg, 95% confidence interval –1.59 to 1.67 kg; p = 0.964). Weight change by centre varied, with 15 intervention participants at one centre losing an average of 4 kg [standard deviation (SD) 4.30 kg] and 18 control group participants gaining on average 3 kg (SD 4.30 kg). In contrast, 21 intervention participants at another centre lost an average of 0.5 kg (SD 6.89 kg), whereas 24 participants in the control group lost 3 kg (SD 9.15 kg). There were no significant differences in change in weight, body mass index or waist circumference at the 3- and 12-month assessments. Laboratory and vital signs were unchanged at 12 months.

The intervention had no overall effect on dietary intake, as measured by the Dietary Instrument for Nutrition Education (DINE); physical activity at baseline was similarly low in both groups. At the 3-month assessment, weekend moderate or vigorous physical activity was significantly higher in the intervention arm, but this difference had disappeared by 12 months.

Self-reported quality of life (QoL), measured using the Short Form questionnaire-36 items, suggested higher QoL post randomisation in the intervention group for physical functioning and bodily pain, but a higher level of emotional well-being in the control group. On the main measure of the EQ-5D-5L, there was no significant difference between the groups. However, on the ‘thermometer’ health scale, the control group showed more improvement at 12 months, with a difference of 4.4 points (p = 0.028). For self-reported depressive symptoms, measured using the Patient Health Questionnaire-9, there was minimal change in both groups over time. In terms of perceptions of weight problems, the B-IPQ total score showed a small improvement in both groups over time, although the changes in the eight dimensions of the B-IPQ were mixed. There were
no significant differences between the groups for the total score or any dimension. For both groups, the observer-rated Brief Psychiatric Rating Scale showed little change over time, with no significant difference between groups.

Twelve participants (eight in the control arm and four in the intervention arm) attended one or more weight loss programmes outside the trial at 3 months, of whom five were still attending at 12 months. At 12 months, 25 participants (7.4%; 8 in the control arm and 17 in the intervention arm) reported attending a weight loss programme outside the trial.

Anonymous intervention session feedback was invited at all seven group sessions, and 708 forms were returned. Overall, the majority (≈90%) of responses were positive, with 87.2% of participants agreeing that the sessions had met their needs. Three-quarters of the free-text comments were also positive. As feedback could not be linked to individual outcomes, these were analysed by centre (five were excluded, owing to no site code). There were no significant correlations between mean weight change and mean feedback scores for centres at 3 or 12 months (Spearman’s rank-order correlation = –0.20, p = 0.476, and Spearman’s rank-order correlation = 0.042, p = 0.454, respectively).

**Adverse events**

A total of 46 adverse events occurred in 37 intervention participants and 34 adverse events occurred in 26 control participants. Fifty per cent of adverse events in both groups were psychiatric hospitalisation. Four deaths were reported, all in the intervention group; the causes were pulmonary embolism following a ruptured Achilles tendon; left ventricular hypertrophy, hypertension and obesity; diabetic ketoacidosis leading to cardiac arrest; and myocardial infarction. Three of the deaths occurred during the trial and one occurred 37 days after trial completion.

**Cost-effectiveness**

The incremental cost-effectiveness ratio (ICER) from the health-care perspective was £246,921 per QALY gained and the ICER from the societal perspective (including employment and education for patients and informal care) was £367,543 per QALY gained.

**Process evaluation**

Both the participants and the facilitators described how the intervention was popular and well received. The participants particularly enjoyed meeting others facing the same challenge of managing weight. It was relatively easy to fill places on the STructured lifestyle Education for People With SchizophrEnia, schizoaffective disorder and first episode psychosis programme (STEPWISE) course, indicating a high level of interest in weight management programmes among people with severe mental illness.

The process evaluation found potential barriers to self-management at the level of the individual’s psychological functioning (e.g. cognitive or attention deficit) and participative capabilities (e.g. low income, anxiety about social interaction), as well as the attitudes of family members and health professionals (paternalism and gatekeeping). Detailed case studies suggested that achieving and maintaining weight loss was particularly difficult for those with first episode psychosis (< 3 years since antipsychotic treatment initiation) and for those with more severe symptoms.

Interviews with developers suggested that the intervention was well grounded in behaviour change theory and had a high level of acceptability to participants. Facilitators reported that they understood and constructed value for the intervention, but were sometimes sceptical about the commitment of senior NHS management to the programme and rarely felt adequately resourced at an organisational level. They would have preferred to have been kept abreast of changes in body weight to assess the effects of the programme on its participants. Facilitators anticipated changing STEPWISE if adopted at the sites, or integrating ideas from it into their own practice if it did not. Although there were opportunities for sharing stories and action-planning, facilitators felt that they needed greater feedback on biomedical and lifestyle data during the sessions to support individuals better.
Analysis against the logic model highlighted the potential role for quality assurance infrastructure in raising and maintaining the quality of delivery. Facilitator training courses and materials were valued and facilitators were generally skilled and motivated. Senior management commitment was generally good, but this did not always translate into appropriate resourcing, and gatekeepers did not always refer eligible patients. The availability of taxi fares for group attendance played a key part in patient engagement. The work of programme and case management was almost always described as inadequately resourced and the number of facilitators who left the trial was high (an average of 20% over 40 weeks). The reason for this was not formally assessed but was often related to work promotions rather than discontent with the intervention.

The fidelity assessment indicated that the delivery was largely as planned, with the mental health care professionals avoiding didactic teaching while adopting facilitative behaviours that allowed the participants to contribute to the groups.

**Conclusions**

Despite concerns about the ability to recruit and retain people with schizophrenia, the STEPWISE trial was completed successfully within the original time frame; however, the STEPWISE intervention was neither clinically effective nor cost-effective. Current National Institute for Health and Care Excellence guidance recommends that lifestyle programmes should be offered to people with severe mental illness, but does not state how these should be commissioned. The results of this trial suggest that lifestyle programmes that have been shown to be effective in other populations, such as in people with diabetes mellitus, are not necessarily effective in people with schizophrenia.

**Recommendations for research**

Further research should investigate if:

- a more intensive lifestyle management programme with longer periods of maintenance support, complemented by objective measures of weight, diet and exercise, delivered by more experienced facilitators or by people from different professional backgrounds is clinically effective and cost-effective
- a more flexible approach, including both group and one-to-one sessions, is more effective
- a broader approach, incorporating adjustment of antipsychotic treatments and the use of adjunctive pharmacological interventions, may be required
- it is possible to overcome the barriers to attendance at lifestyle management programmes
- other formats, including family members or carers, would be more effective
- lifestyle management programmes should be tailored on the basis of the duration of psychotic illness; for example, preventative approaches for people with first episode psychosis may need to be different from those for people with more established disease
- a lifestyle intervention should be combined with specific medication review and/or pharmacological approaches to weight management.

**Trial registration**

This trial is registered as ISRCTN19447796.

**Funding**

Funding for this study was provided by the Health Technology Assessment programme of the National Institute for Health Research.
Criteria for inclusion in the Health Technology Assessment journal

Reports are published in Health Technology Assessment (HTA) if (1) they have resulted from work for the HTA programme, and (2) they are of a sufficiently high scientific quality as assessed by the reviewers and editors.

Reviews in Health Technology Assessment are termed ‘systematic’ when the account of the search appraisal and synthesis methods (to minimise biases and random errors) would, in theory, permit the replication of the review by others.

HTA programme

The HTA programme, part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the effectiveness, costs and broader impact of health technologies for those who use, manage and provide care in the NHS. ‘Health technologies’ are broadly defined as all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care.

The journal is indexed in NHS Evidence via its abstracts included in MEDLINE and its Technology Assessment Reports inform National Institute for Health and Care Excellence (NICE) guidance. HTA research is also an important source of evidence for National Screening Committee (NSC) policy decisions.

For more information about the HTA programme please visit the website: http://www.nets.nihr.ac.uk/programmes/hta

This report

The research reported in this issue of the journal was funded by the HTA programme as project number 12/28/05. The contractual start date was in October 2013. The draft report began editorial review in October 2017 and was accepted for publication in February 2018. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The HTA editors and publisher have tried to ensure the accuracy of the authors’ report and would like to thank the reviewers for their constructive comments on the draft document. However, they do not accept liability for damages or losses arising from material published in this report.

This report presents independent research funded by the National Institute for Health Research (NIHR). The views and opinions expressed by authors in this publication are those of the authors and do not necessarily reflect those of the NHS, the NIHR, NETSCC, the HTA programme or the Department of Health and Social Care. If there are verbatim quotations included in this publication the views and opinions expressed by the interviewees are those of the interviewees and do not necessarily reflect those of the authors, those of the NHS, the NIHR, NETSCC, the HTA programme or the Department of Health and Social Care.

© Queen’s Printer and Controller of HMSO 2018. This work was produced by Holt et al. under the terms of a commissioning contract issued by the Secretary of State for Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.

Published by the NIHR Journals Library (www.journalslibrary.nihr.ac.uk), produced by Prepress Projects Ltd, Perth, Scotland (www.prepress-projects.co.uk).
NIHR Journals Library Editor-in-Chief

Professor Ken Stein  Chair of HTA and EME Editorial Board and Professor of Public Health, University of Exeter Medical School, UK

NIHR Journals Library Editors

Professor Ken Stein  Chair of HTA and EME Editorial Board and Professor of Public Health, University of Exeter Medical School, UK
Professor Andrée Le May  Chair of NIHR Journals Library Editorial Group (HS&DR, PGfAR, PHR journals)
Professor Matthias Beck  Professor of Management, Cork University Business School, Department of Management and Marketing, University College Cork, Ireland
Dr Tessa Crilly  Director, Crystal Blue Consulting Ltd, UK
Dr Eugenia Cronin  Senior Scientific Advisor, Wessex Institute, UK
Dr Peter Davidson  Consultant Advisor, Wessex Institute, University of Southampton, UK
Ms Tara Lamont  Scientific Advisor, NETSCC, UK
Dr Catriona McDaid  Senior Research Fellow, York Trials Unit, Department of Health Sciences, University of York, UK
Professor William McGuire  Professor of Child Health, Hull York Medical School, University of York, UK
Professor Geoffrey Meads  Professor of Wellbeing Research, University of Winchester, UK
Professor John Norrie  Chair in Medical Statistics, University of Edinburgh, UK
Professor John Powell  Consultant Clinical Adviser, National Institute for Health and Care Excellence (NICE), UK
Professor James Raftery  Professor of Health Technology Assessment, Wessex Institute, Faculty of Medicine, University of Southampton, UK
Dr Rob Riemsma  Reviews Manager, Kleijnen Systematic Reviews Ltd, UK
Professor Helen Roberts  Professor of Child Health Research, UCL Great Ormond Street Institute of Child Health, UK
Professor Jonathan Ross  Professor of Sexual Health and HIV, University Hospital Birmingham, UK
Professor Helen Snooks  Professor of Health Services Research, Institute of Life Science, College of Medicine, Swansea University, UK
Professor Jim Thornton  Professor of Obstetrics and Gynaecology, Faculty of Medicine and Health Sciences, University of Nottingham, UK
Professor Martin Underwood  Warwick Clinical Trials Unit, Warwick Medical School, University of Warwick, UK

Please visit the website for a list of editors: www.journalslibrary.nihr.ac.uk/about/editors

Editorial contact: journals.library@nihr.ac.uk